PEPG
PepGen Inc.
$5.66
-$0.08(-1.39%)
48
Overall
60
Value
63
Tech
23
Quality
Market Cap
$149.24M
Volume
314.35K
52W Range
$0.88 - $6.72
Target Price
$10.00
Company Overview
| Mkt Cap | $149.24M | Price | $5.66 |
| Volume | 314.35K | Change | -1.39% |
| P/E Ratio | -1.7 | Open | $5.74 |
| Revenue | -- | Prev Close | $5.74 |
| Net Income | $-90.0M | 52W Range | $0.88 - $6.72 |
| Div Yield | N/A | Target | $10.00 |
| Overall | 48 | Value | 60 |
| Quality | 23 | Technical | 63 |
No chart data available
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Latest News
PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PEPG | $5.66 | -1.4% | 314.35K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |